Cabozantinib and the moving field of systemic treatments in advanced hepatocellular carcinoma

被引：3

作者：

Allaire, Manon ^{[1
,2
]}

Nault, Jean Charles ^{[3
,4
]}

机构：

[1] CHU Cote Nacre, Serv Hepatogastroenterol & Nutr, Caen, France

[2] Fac Med Bichat, Ctr Rech Inflammat, UMR 1149, Paris, France

[3] CHU Jean Verdier, Serv Hepatol, Bondy, France

[4] Inst Natl Sante & Rech Med, UMR 1162, Genom Fonct Tumeurs Solides, Paris, France

来源：

HEPATOBILIARY SURGERY AND NUTRITION | 2019年 / 8卷 / 01期

关键词：

SORAFENIB;

D O I：

10.21037/hbsn.2018.10.12

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：53 / 55

页数：3

共 10 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[3] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].

Cheng, Ann-Lii ;

Kang, Yoon-Koo ;

Chen, Zhendong ;

Tsao, Chao-Jung ;

Qin, Shukui ;

Kim, Jun Suk ;

Luo, Rongcheng ;

Feng, Jifeng ;

Ye, Shenglong ;

Yang, Tsai-Sheng ;

Xu, Jianming ;

Sun, Yan ;

Liang, Houjie ;

Liu, Jiwei ;

Wang, Jiejun ;

Tak, Won Young ;

Pan, Hongming ;

Burock, Karin ;

Zou, Jessie ;

Voliotis, Dimitris ;

Guan, Zhongzhen .

LANCET ONCOLOGY, 2009, 10 (01) :25-34

[4] Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].

El-Khoueiry, Anthony B. ;

Sangro, Bruno ;

Yau, Thomas ;

Crocenzi, Todd S. ;

Kudo, Masatoshi ;

Hsu, Chiun ;

Kim, Tae-You ;

Choo, Su-Pin ;

Trojan, Jorg ;

Welling, Theodore H., III ;

Meyer, Tim ;

Kang, Yoon-Koo ;

Yeo, Winnie ;

Chopra, Akhil ;

Anderson, Jeffrey ;

dela Cruz, Christine ;

Lang, Lixin ;

Neely, Jaclyn ;

Tang, Hao ;

Dastani, Homa B. ;

Melero, Ignacio .

LANCET, 2017, 389 (10088) :2492-2502

[5]

European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019

[6] Hepatocellular carcinoma [J].

Forner, Alejandro ;

Reig, Maria ;

Bruix, Jordi .

LANCET, 2018, 391 (10127) :1301-1314

[7] AASLD guidelines for the treatment of hepatocellular carcinoma [J].

Heimbach, Julie K. ;

Kulik, Laura M. ;

Finn, Richard S. ;

Sirlin, Claude B. ;

Abecassis, Michael M. ;

Roberts, Lewis R. ;

Zhu, Andrew X. ;

Murad, M. Hassan ;

Marrero, Jorge A. .

HEPATOLOGY, 2018, 67 (01) :358-380

[8] Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial [J].

Kudo, Masatoshi ;

Finn, Richard S. ;

Qin, Shukui ;

Han, Kwang-Hyub ;

Ikeda, Kenji ;

Piscaglia, Fabio ;

Baron, Ari ;

Park, Joong-Won ;

Han, Guohong ;

Jassem, Jacek ;

Blanc, Jean Frederic ;

Vogel, Arndt ;

Komov, Dmitry ;

Evans, T. R. Jeffry ;

Lopez, Carlos ;

Dutcus, Corina ;

Guo, Matthew ;

Saito, Kenichi ;

Kraljevic, Silvija ;

Tamai, Toshiyuki ;

Ren, Min ;

Cheng, Ann-Lii .

LANCET, 2018, 391 (10126) :1163-1173

[9] Sorafenib in advanced hepatocellular carcinoma [J].

Llovet, Josep M. ;

Ricci, Sergio ;

Mazzaferro, Vincenzo ;

Hilgard, Philip ;

Gane, Edward ;

Blanc, Jean-Frederic ;

Cosme de Oliveira, Andre ;

Santoro, Armando ;

Raoul, Jean-Luc ;

Forner, Alejandro ;

Schwartz, Myron ;

Porta, Camillo ;

Zeuzem, Stefan ;

Bolondi, Luigi ;

Greten, Tim F. ;

Galle, Peter R. ;

Seitz, Jean-Francois ;

Borbath, Ivan ;

Haussinger, Dieter ;

Giannaris, Tom ;

Shan, Minghua ;

Moscovici, Marius ;

Voliotis, Dimitris ;

Bruix, Jordi .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :378-390

[10] REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. [J].

Zhu, Andrew X. ;

Kang, Yoon-Koo ;

Yen, Chia-Jui ;

Finn, Richard S. ;

Galle, Peter R. ;

Llovet, Josep M. ;

Assenat, Eric ;

Brandi, Giovanni ;

Lim, Ho Yeong ;

Pracht, Marc ;

Rau, Kun-Ming ;

Merle, Philippe ;

Motomura, Kenta ;

Ohno, Izumi ;

Daniele, Bruno ;

Shin, Dongbok ;

Gerken, Guido ;

Abada, Paolo ;

Hsu, Yanzhi ;

Kudo, Masatoshi .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 →